Publication | Open Access

Clinical and pharmacological phase I evaluation of Exherin™ (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours

N-cadherin-expressing Solid TumoursPharmacological PhaseMedicineSelective Anti-n-cadherin PeptidePathologyCancer Cell BiologyTumor TargetingCancer TreatmentOncologyRadiation OncologyCancer ResearchTumor Biology